Ureteroscopic management of upper tract urothelial carcinoma (UTUC) in patients with Lynch Syndrome (hereditary nonpolyposis colorectal cancer syndrome)

BJU International

Volumn 112, Issue 6, 2013, Pages 813-819

  Hubosky, Scott G ^a   Boman, Bruce M ^a   Charles, Sarah ^a   Bibbo, Marluce ^a   Bagley, Demetrius H ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

hereditary nonpolyposis colorectal cancer; kidney neoplasms; Lynch Syndrome; ureteric neoplasms; ureteroscopy

Indexed keywords

PROTEIN MSH2;

ADULT; AGED; ARTICLE; BLADDER TUMOR; CANCER CLASSIFICATION; CANCER CONTROL; CANCER GRADING; CANCER SIZE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL FEATURE; DEMOGRAPHY; ENDOSCOPIC SURGERY; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC COUNSELING; GERM LINE; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HISTOPATHOLOGY; HOLMIUM LASER; HUMAN; KIDNEY PRESERVATION; LASER SURGERY; MALE; MSH 2 GENE; NEODYMIUM YAG LASER; NEPHROURETERECTOMY; ONSET AGE; PATIENT REFERRAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEGMENTAL URETERECTOMY; TRANSITIONAL CELL CARCINOMA; URETER SURGERY; URETEROSCOPY; UROGENITAL TRACT CANCER; UROLOGIST;

HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; KIDNEY NEOPLASMS; LYNCH SYNDROME; URETERIC NEOPLASMS; URETEROSCOPY;

ADULT; AGED; CARCINOMA, TRANSITIONAL CELL; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MUTATION; MUTS HOMOLOG 2 PROTEIN; NEOPLASM GRADING; NEOPLASMS, MULTIPLE PRIMARY; NEPHRECTOMY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES; URETERAL NEOPLASMS; URETEROSCOPY;

EID: 84884287396     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12008     Document Type: Article

References (26)

1. Chen GL, Bagley DH,. Ureteroscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys. J Urol 2000; 164: 1173-1176
2. Elliott DS, Segura JW, Lightner D, Patterson DE, Blute ML,. Is nephroureterectomy necessary in all cases of upper tract transitional cell carcinoma? Long-term results of conservative endourologic management of upper tract transitional cell carcinoma in individuals with a normal contralateral kidney. Urology 2001; 58: 174-178
3. Vasen HF, Moslein G, Alonso A, et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis colon cancer). J Med Genet 2007; 44: 353-362
4. Crockett DG, Wagner DG, Holmang S, Johansson SL, Lynch HT,. Upper urinary tract carcinoma in Lynch Syndrome cases. J Urol 2011; 185: 1627-1630
5. Vasen HF, Wijnen J, Menko FH, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996; 110: 1020-1027
6. Audenet F, Colin P, Yates DR, et al. A proportion of hereditary upper urinary tract urothelial carcinomas are misclassified as sporadic according to a multi-institutional database analysis: proposal of patient-specific risk identification tool. BJU Int 2012; doi: 10.1111/j.1464-410X.2012.11298.x [Epub ahead of print]
7. Keeley FX, Bibbo M, Bagley DH,. Ureteroscopic treatment and surveillance of upper tract transitional cell carcinoma. J Urol 1997; 157: 1560-1565
8. Tawfiek E, Bibbo M, Bagley DH,. Ureteroscopic biopsy: technique and specimen preparation. Urology 1997; 50: 117-119
9. Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG,. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 1998; 52: 594-601
10. Keeley FX, Kulp DA, Bibbo M, McCue PA, Bagley DH,. Diagnostic accuracy of ureteroscopic biopsy in upper tract transitional cell carcinoma. J Urol 1997; 157: 33-37
11. Daneshmand MS, Quek ML, Huffman JL,. Endoscopic management of upper urinary tract transitional cell carcinoma: long term experience. Cancer 2003; 98: 55-60
12. Brown GA, Matin SF, Busby JE, et al. Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy. Urology 2007; 70: 252-256
13. Watson P, Lynch HT,. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 1993; 71: 677-685
14. Watson P, Vasen HF, Mecklin JP, et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch Syndrome. Int J Cancer 2008; 123: 444-449
15. Sijmons RH, Kiemeney LA, Witjes JA, Vasen HF,. Urinary tract cancer and hereditary nonpolyposis colorectal cancer: risks and screening options. J Urol 1998; 160: 466-470
16. Vasen HF, Mecklin JP, Khan PM, Lynch HT,. The international collaborative group on HNPCC. Anticancer Res 1994; 14: 1661-1664
17. Genega EM, Kapali M, Torres-Quinones M, et al. Impact of the 1998 World Health Organization/International Society of Urological Pathology classification system for urothelial neoplasms of the kidney. Mod Pathol 2005; 18: 11-18
18. Montironi R, Lopez-Beltran A,. The 2004 WHO classification of bladder tumors: a summary and commentary. Int J Surg Pathol 2005; 13: 143-153
19. Holmang S, Johansson SL,. Bilateral metachronous ureteral and renal pelvic carcinomas: incidence, clinical presentation, histopathology, treatment and outcome. J Urol 2006; 175: 69-73
20. Charbit L, Gendreau MC, Mee S, et al. Tumors of the upper urinary tract: 10 years experience. J Urol 1991; 146: 1243-1246
21. Huang WC, Levey AS, Serio AM, et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 2006; 7: 735-740
22. Cornu TN, Roupret M, Carpentier X, et al. Oncologic control obtained after exclusive flexible ureteroscopic management of upper urinary tract urothelial cell carcinoma. World J Urol 2010; 28: 151-156
23. Thompson RH, Krambeck AE, Lohse CM, Elliott DS, Patterson DE, Blute ML,. Elective endoscopic management of transitional cell carcinoma first diagnosed in the upper tract. BJU Int 2008; 102: 1107-1110
24. Matsui Y, Utsunomiya N, Ichioka K, et al. Risk factors for subsequent development of bladder cancer after primary transitional cell carcinoma of the upper tract. Urology 2005; 65: 279-283
25. O'Brien T, Ray E, Singh R, Coker B, Beard R,. Prevention of bladder tumors after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicenter, randomized clinical trial of a single postoperative intravesical dose of Mitomycin C (the ODMIT-C Trial). Eur Urol 2011; 60: 703-710
26. Vasen HF,. Clinical diagnosis and management of hereditary colorectal cancer syndromes. J Clin Oncol 2000; 18 (Suppl.): 81s-92s